Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Matinas BioPharma (DE:6LJ)
FRANKFURT:6LJ
Matinas BioPharma (6LJ) Stock Price & Analysis
0 Followers
6LJ Stock Chart & Stats
Day’s Range€0.14 - €0.14
52-Week Range― - ―
Previous Close€0.14
Volume0.00
Average Volume (3M)N/A
Market Cap
$41.93M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 08, 2024EPS Estimate
-€0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.56Price Target Upside294.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Matinas BioPharma News
PremiumCompany Announcements
Matinas BioPharma’s Multi-Million Share Sale and Lock-Up Deal
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
0.97% Other Institutional Investors
99.03% Public Companies and
Individual Investors
6LJ FAQ
What was Matinas BioPharma’s price range in the past 12 months?
Currently, no data Available
What is Matinas BioPharma’s market cap?
Currently, no data Available
When is Matinas BioPharma’s upcoming earnings report date?
Matinas BioPharma’s upcoming earnings report date is May 08, 2024 which is in 3 days.
How were Matinas BioPharma’s earnings last quarter?
Matinas BioPharma released its earnings results on Mar 27, 2024. The company reported -€0.019 earnings per share for the quarter, beating the consensus estimate of -€0.028 by €0.009.
Is Matinas BioPharma overvalued?
According to Wall Street analysts Matinas BioPharma’s price is currently Undervalued.
Does Matinas BioPharma pay dividends?
Matinas BioPharma does not currently pay dividends.
What is Matinas BioPharma’s EPS estimate?
Matinas BioPharma’s EPS estimate is -€0.03.
How many shares outstanding does Matinas BioPharma have?
Currently, no data Available
What happened to Matinas BioPharma’s price movement after its last earnings report?
Matinas BioPharma reported an EPS of -€0.019 in its last earnings report, beating expectations of -€0.028. Following the earnings report the stock price went down -20.408%.
Which hedge fund is a major shareholder of Matinas BioPharma?
Currently, no hedge funds are holding shares in DE:6LJ
---
Matinas BioPharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€0.56 (294.34% Upside)
€0.56 (294.34% Upside)
Blogger Sentiment
Bullish
DE:6LJ Sentiment 100%
Sector Average 71%
Sector Average 71%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.24%
12-Months-Change
Fundamentals
Return on Equity
-82.11%
Trailing 12-Months
Asset Growth
-16.85%
Trailing 12-Months
Company Description
Matinas BioPharma
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.
---
6LJ Earnings Call
Q4 2024
0:00 / 0:00
---
6LJ Stock 12 Months Forecast
Average Price Target
€0.56
▲(294.34% Upside)
Technical Analysis
Matinas BioPharma
―
Bioline RX Ltd Sponsored ADR
―
G1 Therapeutics
―
Akebia Therapeutics
―
Ardelyx
―
Best Analysts Covering 6LJ
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-49.88%
reiterated a buy rating last month
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -49.88% per trade.
---